UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
Filed by the registrant ☒
Filed by a party other than the Registrant ☐
Check the
appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted by
Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material under § 240.14a-12 |
ADC Therapeutics
SA
(Name of registrant as specified in its charter)
(Name of person(s) filing proxy statement, if other than the registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☐ | Fee paid previously with preliminary materials |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per
Exchange Act Rules 14a-6(i)(1) and 0-11 |
Online
Go
to www.envisionreports.com/ADCT or scan the QR code — login details are located
in the shaded bar below.
Electronic
voting instructions must be received by Computershare no later than November 6, at 11:59 p.m. EST / November 7 at 5:59 a.m. CET
Proxy
cards by mail must be received by Computershare no later than November 4, at 11:59 p.m. EST / November 5 at 5:59 a.m. CET
ADC
Therapeutics SA Shareholder Meeting Notice
Important
Notice Regarding the Availability of Proxy Materials for the ADC Therapeutics SA Extraordinary Shareholder Meeting to be Held on Monday,
November 11, 2024 at 10:00 a.m. EST / 4:00 p.m. CET
at
Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland
You
are receiving this notice that the proxy materials for the extraordinary shareholders’ meeting are available on the Internet. Follow
the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the extraordinary
meeting are on the reverse side. Your vote is important!
This
communication presents only an overview of the more complete proxy materials that are available to you on the internet. You are encouraged
to access and view the complete proxy materials before voting. This proxy materials are available for viewing, printing and downloading
at
https://ir.adctherapeutics.com/sec-filings/annual-reports-and-proxies/default.aspx
Additionally,
you can find a copy of the proxy statement on the website of the U.S. Securities and Exchange Commission (the “SEC”) at sec.gov.
You may also obtain a printed copy of the proxy materials, at no cost, upon written or oral request to us at the following address: Investor
Relations, ADC Therapeutics SA, c/o ADC Therapeutics America, Inc., 430 Mountain Avenue, 4th Floor, Murray Hill, NJ 07974; (908) 731-5556.
Easy
Online Access — View your proxy materials and vote.
Step 1: Go to
www.envisionreports.com/ADCT.
Step
2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in.
Step
4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.
When
you go online, you can also help the environment by consenting to receive electronic delivery of future materials.
Obtaining
a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge
to you for requesting a copy. Please make your request as instructed on the reverse side on or before October 28, 2024, to facilitate
timely delivery.
ADC
Therapeutics SA Shareholder Meeting Notice
ADC
Therapeutics SA’s Extraordinary General Meeting of Shareholders will be held on Monday, November 11, 2024, at the headquarter of
ADC Therapeutics SA, Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland, at 10:00 a.m. EST / 4:00 p.m. CET
Proposals
to be voted on at the meeting are listed below along with the Board of Directors’ recommendations.
The
Board of Directors recommends a vote FOR Proposals 1 and 2:
Agenda
and Proposals of the Board of Directors
Proposals
to be voted on at the meeting are listed below along with the Board of Directors’ recommendations.
1.
Approving amendments to Article 4a of the articles of association to increase the Company’s capital range
The
Board of Directors proposes that the amendments to Article 4a of the articles of association to increase the Company’s capital
range be approved. The Board of Directors recommends that you vote “FOR” this proposal.
2.
Approving amendments to Article 4c of the articles of association to increase the Company’s conditional share capital for
financing, acquisitions and other purposes
The
Board of Directors proposes that the amendments to Article 4c of the articles of association to increase the Company’s conditional
share capital for financing, acquisitions and other purposes be approved.
The
Board of Directors recommends that you vote “FOR” this proposal.
Here’s
how to order a copy of the proxy materials and select delivery preferences:
Current
and future delivery requests can be submitted using the options below.
If
you request an email copy, you will receive an email with a link to the current meeting materials.
PLEASE
NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.
| — | Internet
– Go to www.envisionreports.com/ADCT.
Click Cast Your Vote or Request Materials. |
| — | Phone
– Call us free of charge at 1-866-641-4276. |
| — | Email
– Send an email to investorvote@computershare.com
with “Proxy Materials ADC Therapeutics SA” in the subject line. Include your
full name and address, plus the number located in the shaded bar on the reverse side, and
state that you want a paper copy of the meeting materials. |
To
facilitate timely delivery, all requests for a paper copy of proxy materials must be received by October 28, 2024.
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Nov 2024 to Dec 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Dec 2023 to Dec 2024